Tazocilin (4 gm+0.5 gm)/vial (IV Infusion)

Title

• Piperacillin and Tazobactam Injection

Categories

• Medicine
• Antibiotic
• Pharmacology

Indications

• Intra-abdominal infections treatment
• Skin and skin structure infections treatment
• Community-acquired pneumonia treatment
• Nosocomial pneumonia treatment
• Postpartum endometritis treatment

Pharmacology

• Broad spectrum antibacterial activity
• Bactericidal activity
• Inhibition of cell wall synthesis
• Inhibition of beta-lactamases
• Enhancement of antibiotic spectrum

Dosage & Administration

• Administered by intravenous infusion
• Usual total daily dose for adults is 3.375g
• Treatment duration of 7 to 10 days for adults
• Initial presumptive treatment for nosocomial pneumonia
• Dosage adjustment for pediatric patients based on age and weight

Interaction

• Potential interaction with aminoglycosides
• Potential interaction with probenecid
• Coagulation parameters testing for anticoagulant interaction
• Potential interaction with vecuronium
• Potential interaction with methotrexate

Contraindications

• Contraindicated in patients with history of allergic reactions to penicillins, cephalosporins, or beta-lactamase inhibitors

Side Effects

• Adverse events involving skin, gastrointestinal, and general disorders
• Immune hypersensitivity reactions
• Infections, metabolism, and musculoskeletal disorders
• Psychiatric and vascular disorders
• Respiratory, thoracic, and mediastinal disorders

Pregnancy & Lactation

• Crosses the placenta in humans
• Insufficient data on risk for major birth defects and miscarriage
• Excretion in human milk
• No data on effects on breastfed child

Precautions & Warnings

• Serious hypersensitivity reactions reported
• Potential severe cutaneous adverse reactions
• Hematological effects monitoring
• Nephrotoxicity in critically ill patients
• Clostridium difficile associated diarrhea evaluation

Use in Special Populations

• Supported use in pediatric patients
• Dosage adjustment in geriatric patients and patients with renal impairment
• No dosage adjustment needed in hepatic impairment
• Increased incidence of fever and rash in cystic fibrosis patients

Overdose Effects

• Reported overdose events including nausea, vomiting, and diarrhea
• Potential neuromuscular excitability or convulsions

Therapeutic Class

• Broad spectrum penicillins
• Other beta-lactam Antibiotics

Reconstitution

• Administration by intravenous infusion over 30 minutes
• Withdrawal and mixing process with Sodium Chloride solution
• Immediate use after reconstitution
• Storage and discard guidelines

Storage Conditions

• Keep below 30°C temperature
• Protect from light and moisture
• Keep out of the reach of children

Related Brands

• Brodactam (2 gm+0.25 gm)/vial (IV Infusion) - synovia-pharma-plc
• Tazocilin (2 gm+0.25 gm)/vial (IV Infusion) - square-pharmaceuticals-plc
• Tazocin (4 gm+0.5 gm)/vial (IV Infusion) - pfizer
• Tazopen (2 gm+0.25 gm)/vial (IV Infusion) - renata-limited
• Tazobac (4 gm+0.5 gm)/vial (IV Infusion) - aci-limited